AATec Medical获得 400万欧元资金，以推进其主要呼吸系统药物候选进入临床开发阶段-动脉网

AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development

D-Pharm 等信源发布 2025-04-22 09:55



可切换为仅中文







AATec Medical GmbH (AATec), a biotech company developing a multi-product platform for the treatment of

AATec Medical GmbH（AATec），一家正在开发用于治疗的多产品平台的生物技术公司，

respiratory diseases

呼吸道疾病

based on recombinant alpha-1 antitrypsin (AAT), announced that it has secured EUR 4 million in a pre-series A financing from Germany’s Federal Agency for Disruptive Innovation (SPRIND) and high-net worth individuals investors, industry experts and single family offices.

基于重组α-1抗胰蛋白酶（AAT），宣布其已从德国联邦颠覆性创新局（SPRIND）、高净值个人投资者、行业专家及单一家族办公室获得了400万欧元的A轮融资。

The proceeds will be used to advance the development of ATL-105, AATec’s lead drug candidate in chronic respiratory inflammation and infectious respiratory diseases. ATL-105 will initially be developed for the treatment of non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory respiratory disease without any causative therapies.

这笔资金将用于推动AATec公司在慢性呼吸道炎症和传染性呼吸道疾病领域的主导候选药物ATL-105的开发。ATL-105将首先针对非囊性纤维化支气管扩张症（NCFB）进行开发，这是一种尚无针对性疗法的慢性炎症性呼吸道疾病。

Current NCFB treatment is limited to symptomatic therapy including antibiotics, macrolides, and physical therapy. The funding will support IND-enabling activities and position ATL-105 for entry into clinical trials by 2026..

目前，NCFB 的治疗仅限于包括抗生素、大环内酯类和物理疗法在内的对症治疗。这笔资金将支持 IND 所需的活动，并使 ATL-105 能够在 2026 年进入临床试验阶段。

Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “This funding is a crucial step toward preparing ATL-105 for clinical development. Non-CF bronchiectasis significantly impacts patients’ quality of life, and current treatment options are limited. We believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide.

AATec联合创始人兼首席执行官鲁迪格·扬科夫斯基博士评论道：“这笔资金是为ATL-105的临床开发做准备的关键一步。非囊性纤维化支气管扩张症显著影响患者的生活质量，而目前的治疗选择有限。我们相信，ATL-105有潜力为全球数百万患者提供有意义的治疗进展。”

In Western countries alone, more than 3 million patients suffer from NCFB. Thanks to our novel protein inhalation approach, ATL-105 is delivered directly to the lungs, maximizing therapeutic effectiveness at the primary site of inflammation and minimizing systemic side effects. The support from SPRIND validates our innovative approach and highlights the transformative potential of our technology.”.

仅在西方国家，就有超过 300 万患者受到 NCFB 的困扰。得益于我们新颖的蛋白质吸入方法，ATL-105 可直接递送到肺部，在炎症的主要部位最大化治疗效果，并将全身副作用降至最低。SPRIND 的支持验证了我们的创新方法，并突显了我们技术的变革潜力。”

Sigrid Koeth, Innovation Manager at SPRIND, added: “At SPRIND, we’re looking for ideas that can fundamentally change things for the better. We believe that AATec’s approach using recombinant alpha-1 antitrypsin has great potential in a wide range of respiratory diseases and infections. Innovations like this can be key in protecting public health and strengthening the resilience of our healthcare systems.”.

SPRIND的创新经理西格丽德·科埃斯补充说：“在SPRIND，我们寻找能够从根本上让事情变得更好的创意。我们认为AATec采用重组α-1抗胰蛋白酶的方法在多种呼吸系统疾病和感染方面具有巨大潜力。这样的创新可以成为保护公共健康和增强医疗系统韧性的关键。”

AATec Medical’s lead product candidate, ATL-105, is based on a novel recombinant alpha‑1 antitrypsin (AAT), a human serine protease inhibitor with broad anti-inflammatory, immunomodulatory and anti-infective properties. Robust preclinical proof-of-principle data demonstrate ATL-105’s excellent safety profile and broad therapeutic potential by effectively targeting key pathological processes in inflammatory lung diseases..

AATec Medical的主打候选产品ATL-105基于一种新型重组α-1抗胰蛋白酶（AAT），这是一种具有广泛抗炎、免疫调节和抗感染特性的丝氨酸蛋白酶抑制剂。强有力的临床前概念验证数据表明，ATL-105通过有效针对炎症性肺病的关键病理过程，展现出卓越的安全性和广泛的治疗潜力。

https://www.bionity.com/en/news/1186066/aatec-medical-secures-eur-4-million-to-advance-lead-respiratory-drug-candidate-to-clinical-development.html

https://www.bionity.com/zh/news/1186066/aatec-medical获得400万欧元以推进主要呼吸药物候选物进入临床开发.html

Signs of developing asthma are evident in the first year of life

生命的第一年中就出现了哮喘发展的迹象。

A new way of looking at chronic illness

一种看待慢性疾病的新方法

Read news

读新闻